Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 4

LA JOLLA PHARMACEUTICAL CO

Form 4 May 14, 2008

FORM 4

OMB APPROVAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB 3235-0287 Number:

5. Relationship of Reporting Person(s) to

Issuer

Check this box if no longer subject to Section 16.

Washington, D.C. 20549

January 31, Expires: 2005

Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Estimated average burden hours per response... 0.5

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

Symbol

1(b).

(Print or Type Responses)

SUTTER MARTIN P

1. Name and Address of Reporting Person *

			LA JOLLA PHARMACEUTICAL CO [LJPC]				AL	(Check all applicable)			
(Last) (First) (Middle) 21 WATERWAY, SUITE 225			3. Date of Earliest Transaction (Month/Day/Year) 05/12/2008					X Director Officer (give below)	Officer (give title Other (specify		
				4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deeme Execution any (Month/Da	Date, if	3. Transacti Code (Instr. 8)	4. Securities of Disposed (Instr. 3, 4 a	of (D)	red (A)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	05/12/2008			Р	2,081,977		\$ 1.89	9,748,643	I	By Essex Woodlands Health Ventures Fund VI, L.P. (1)	
Common Stock								64,400	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 4

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount of Number of Shares
Stock option (right to buy)	\$ 0.69					(2)	12/14/2015	Common Stock	40,00
Warrant (right to buy)	\$ 0.125	05/12/2008		P	520,494	- 05/12/2008	(3)	Common Stock	2,187,1

Reporting Owners

Reporting Owner Name / Address	Relationships					
1 0	Director	10% Owner	Officer	Other		
SUTTER MARTIN P 21 WATERWAY SUITE 225 THE WOODLANDS, TX 77380	X					
^! !						

Signatures

/s/ Martin P.
Sutter

**Signature of Pate Reporting Person

O5/14/2008

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The reporting person is a managing director of the general partner of the general partner of the partnership that owns the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Reporting Owners 2

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 4

- (2) The options vest and become exercisable with respect to 25% of the underlying shares on 12/14/2005 and with respect to an additional 25% of the underlying shares on each of the next three annual anniversaries thereof.
- (3) The right to purchase shares of common stock under the warrant expires upon the earlier of (i) the fifth anniversary of May 12, 2008 and (ii) the date of consummation of any certain extraordinary transactions.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.